Very interesting article this morning on the selection of Canada for the first non-US vaccine plant by Moderna.
The 180M$ investment (split equally between Moderna and the 2 levels of governments) brings more than just a direct investment. It showed the world that Canada has the ecosystem for that.
But more importantly, experts say that a plant is an investment that lasts 30-40 years and even more. They say that offices can be moved, a R&D lab too but not really a plant. They give the example of a 1944 Ayerst plant that was bought back by Wyeth, which was than bought by Pfizer in 2009, which was then acquired by GSK in 2018.
So this bring me to our COVID-19 indication. We don't know much details yet regarding the scope/audience/benefits/efficacy/differentiator/edge over competition of our potential COVID-19 vaccine but we know one thing and it's that NML clearly knows what's missing in the market. So that NML decided to initiate the last of the preclinical steps speaks bold about the need that our vaccine could fill. NML has the worldwide credibility to understand the potential contribution of our COVID-19 technology. That's undisputable. They know their stuff. Again, TLT teamed up with the best. Nothing else.
If NML recommands that we move forward into clinical trial if the last preclinical step is deemed convincing, then that's a simple question of doing the human clinical trial as Dr. Kobasa has been extremely impressed about the nanomolar dose required to destroy many types of enveloped viruses, as per the TLT news release of April 2021 and Feb. 2022. Given that we already know about the toxicity and efficacy of our TLD1433 molecule, thanks to the NMIBC trial, the rest should merely be a formality.
The article I make mention above states that the canadian government has secured 30M-120M doses/year from Moderna. So if TLT's vaccine moves forward, TLT will receive similar magnitude of supply order from the canadian government. And other countries too.
47 vaccines approved by at least one country - Where are vaccines approved? And given the versatility of our TLC-3000 platform, as per a quote from Dr. Mandel, it's expected that such platform is also suited for other type of viruses (like influenza, Zika, simplex herpes, MonkeyPox, ChickenPox, possibly Hepatitis, etc ... as per noted in the TLT news releases).
So all in all, oncology (Ph. 2 NMIBC data) + anti-virus (NML recommandation) would clearly put us on the radar.